382 related articles for article (PubMed ID: 29523488)
21. Flibanserin for female sexual dysfunction.
Reviriego C
Drugs Today (Barc); 2014 Aug; 50(8):549-56. PubMed ID: 25187905
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.
Katz M; DeRogatis LR; Ackerman R; Hedges P; Lesko L; Garcia M; Sand M;
J Sex Med; 2013 Jul; 10(7):1807-15. PubMed ID: 23672269
[TBL] [Abstract][Full Text] [Related]
23. Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials.
Simon JA; Thorp J; Millheiser L
J Womens Health (Larchmt); 2019 Jun; 28(6):769-777. PubMed ID: 30707049
[No Abstract] [Full Text] [Related]
24. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder.
Stahl SM; Sommer B; Allers KA
J Sex Med; 2011 Jan; 8(1):15-27. PubMed ID: 20840530
[TBL] [Abstract][Full Text] [Related]
25. Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.
Goldfischer ER; Breaux J; Katz M; Kaufman J; Smith WB; Kimura T; Sand M; Pyke R
J Sex Med; 2011 Nov; 8(11):3160-72. PubMed ID: 21933348
[TBL] [Abstract][Full Text] [Related]
26. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
Parish SJ; Simon JA; Davis SR; Giraldi A; Goldstein I; Goldstein SW; Kim NN; Kingsberg SA; Morgentaler A; Nappi RE; Park K; Stuenkel CA; Traish AM; Vignozzi L
J Womens Health (Larchmt); 2021 Apr; 30(4):474-491. PubMed ID: 33797277
[No Abstract] [Full Text] [Related]
27. Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis.
Gao Z; Yang D; Yu L; Cui Y
J Sex Med; 2015 Nov; 12(11):2095-104. PubMed ID: 26745616
[TBL] [Abstract][Full Text] [Related]
28. Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin.
Simon JA; Clayton AH; Kim NN; Patel S
Sex Med; 2022 Feb; 10(1):100476. PubMed ID: 34999484
[TBL] [Abstract][Full Text] [Related]
29. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
Parish SJ; Simon JA; Davis SR; Giraldi A; Goldstein I; Goldstein SW; Kim NN; Kingsberg SA; Morgentaler A; Nappi RE; Park K; Stuenkel CA; Traish AM; Vignozzi L
Climacteric; 2021 Dec; 24(6):533-550. PubMed ID: 33792440
[TBL] [Abstract][Full Text] [Related]
30. Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study.
Simon JA; Derogatis L; Portman D; Brown L; Yuan J; Kissling R
J Sex Med; 2018 Mar; 15(3):387-395. PubMed ID: 29502984
[TBL] [Abstract][Full Text] [Related]
31. A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes.
Rochester-Eyeguokan C; Meade L
Diabetes Ther; 2017 Oct; 8(5):991-998. PubMed ID: 28918588
[TBL] [Abstract][Full Text] [Related]
32. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study.
Thorp J; Simon J; Dattani D; Taylor L; Kimura T; Garcia M; Lesko L; Pyke R;
J Sex Med; 2012 Mar; 9(3):793-804. PubMed ID: 22239862
[TBL] [Abstract][Full Text] [Related]
33. Flibanserin for hypoactive sexual desire disorder: place in therapy.
Gelman F; Atrio J
Ther Adv Chronic Dis; 2017 Jan; 8(1):16-25. PubMed ID: 28203348
[TBL] [Abstract][Full Text] [Related]
34. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women.
Fabre LF; Brown CS; Smith LC; Derogatis LR
J Sex Med; 2011 May; 8(5):1411-9. PubMed ID: 21324094
[TBL] [Abstract][Full Text] [Related]
35. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Althof S; Derogatis LR; Greenberg S; Clayton AH; Jordan R; Lucas J; Spana C
J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966
[TBL] [Abstract][Full Text] [Related]
36. Hypoactive sexual desire in women.
Kingsberg SA; Rezaee RL
Menopause; 2013 Dec; 20(12):1284-300. PubMed ID: 24219879
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of safety for flibanserin.
Clayton AH; Brown L; Kim NN
Expert Opin Drug Saf; 2020 Jan; 19(1):1-8. PubMed ID: 31855607
[No Abstract] [Full Text] [Related]
38. Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women.
Clayton AH; Dennerstein L; Pyke R; Sand M
Womens Health (Lond); 2010 Sep; 6(5):639-53. PubMed ID: 20887163
[TBL] [Abstract][Full Text] [Related]
39. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
Koochaki P; Revicki D; Wilson H; Pokrzywinski R; Jordan R; Lucas J; Williams LA; Sadiq A; Krop J
J Womens Health (Larchmt); 2021 Apr; 30(4):587-595. PubMed ID: 33538638
[No Abstract] [Full Text] [Related]
40. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.
Jaspers L; Feys F; Bramer WM; Franco OH; Leusink P; Laan ET
JAMA Intern Med; 2016 Apr; 176(4):453-62. PubMed ID: 26927498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
